VEGF is the primary angiogenic stimulator in CNV and RNV, which has been highlighted by the clinical success of therapeutic agents that inhibit VEGF activity for the treatment of AMD and DR [11,20]. This evidence concerns the gene VEGFA and age-related macular degeneration.